يعرض 1 - 20 نتائج من 1,601 نتيجة بحث عن '"rheumatoide arthritis"', وقت الاستعلام: 0.42s تنقيح النتائج
  1. 1
    Report
  2. 2
    Report
  3. 3
    Academic Journal
  4. 4
    Report
  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal

    المصدر: GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW; VOL: 10; DOC03 /20210414/

    Relation: Allegra A, Oteri G, Alonci A, Bacci F, Penna G, Minardi V, Maisano V, Musolino C. Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. J Craniomaxillofac Surg. 2014 Jun;42(4):279-82. DOI:10.1016/j.jcms.2013.05.014; Bennardo F, Buffone C, Giudice A. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws. Oral Oncol. 2020 Jul;106:104659. DOI:10.1016/j.oraloncology.2020.104659; Bindakhil MA, Mupparapu M. Osteomyelitis of the mandible exhibiting features of medication-related osteonecrosis in a patient with history of tocilizumab treatment. J Orofac Sci. 2018;10(1):153-5.; Brijs K, Miclotte I, Vermeire S, Darche V, Politis C. Osteonecrosis of the jaw in patients with inflammatory bowel disease treated with tumour necrosis factor alpha inhibitors. Int J Oral Maxillofac Surg. 2020 Mar;49(3):317-24. DOI:10.1016/j.ijom.2019.08.007; Cassoni A, Romeo U, Terenzi V, Della Monaca M, Rajabtork Zadeh O, Raponi I, Fadda MT, Polimeni A, Valentini V. Adalimumab: Another Medication Related to Osteonecrosis of the Jaws? Case Rep Dent. 2016;2016:2856926. DOI:10.1155/2016/2856926; Chaitow J, De Benedetti F, Brunner H, Ruperto N, Allen R, Murray K, Schneider R, Woo P, Wright S, Kenwright A, Martini A, Lovell D. Tocilizumab in patients with systemic juvenile idiopathic arthritis; Efficacy data from the placebo-controlled 12-week part of the phase III Tender Trial. Intern Med J. 2011;41(s1):32. DOI:10.1111/j.1445-5994.2010.02466.x; Ciantar M, Adlam DM. Treatment with infliximab: Implications in oral surgery? A case report. Br J Oral Maxillofac Surg. 2007 Sep;45(6):507-10. DOI:10.1016/j.bjoms.2006.06.004; Dinnendahl V, Fricke U, editors. Arzneistoff-Profile. 4 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag; 2010. ISBN: 978-3-7741-9846-3.; Ebker T, Rech J, von Wilmowsky C, Neukam FW, Stockmann P. Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy. Rheumatology (Oxford). 2013 Jan;52(1):218-20. DOI:10.1093/rheumatology/kes351; Fleisher KE, Jolly A, Venkata UD, Norman RG, Saxena D, Glickman RS. Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. J Oral Maxillofac Surg. 2013 Mar;71(3):513-9. DOI:10.1016/j.joms.2012.07.049; Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Mar;113(3):e1-3. DOI:10.1016/j.tripleo.2011.06.023; Goda H, Nakashiro KI, Hino S, Tanaka H, Hamakawa T, Hamakawa H. Possible negative effect of tocilizumab on BRONJ in a patient with methotrexate-associated lymphproliferative disorder. Nippon Koku Geka Gakkai Zasshi. 2013;59(5):346-51. DOI:10.5794/jjoms.59.346; Imaculada de Queiroz Rodrigues M, Ohana de Lima Martins J, Silva PGB, Carlos Ferreira Júnior AE, Quezado Lima Verde ME, Sousa FB, Lima Mota MR, Negreiros Nunes Alves AP. Tocilizumab, a Potent Interleukin-6 Receptor Inhibitor, Decreases Bone Resorption and Increases the Rate of Bacterial Infection After Tooth Extraction in Rats. J Oral Maxillofac Surg. 2020 Dec;78(12):2138-46. DOI:10.1016/j.joms.2020.08.012; Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010 Jan;69(1):88-96. DOI:10.1136/ard.2008.105197; Kallen KJ. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta. 2002 Nov;1592(3):323-43. DOI:10.1016/s0167-4889(02)00325-7; Lescaille G, Coudert AE, Baaroun V, Ostertag A, Charpentier E, Javelot MJ, Tolédo R, Goudot P, Azérad J, Berdal A, Spano JP, Ruhin B, Descroix V. Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients. Bone. 2014 Jan;58:103-7. DOI:10.1016/j.bone.2013.10.002; Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020 Jul;92(7):814-8. DOI:10.1002/jmv.25801; Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007 Dec;65(12):2397-410. DOI:10.1016/j.joms.2007.08.003; Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009 Oct;68(10):1580-4. DOI:10.1136/ard.2008.092866; Pakosch D, Papadimas D, Munding J, Kawa D, Kriwalsky MS. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac Surg. 2013 Dec;17(4):303-6. DOI:10.1007/s10006-012-0379-9; Pichardo SE, van Merkesteyn JP. Evaluation of a surgical treatment of denosumab-related osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Sep;122(3):272-8. DOI:10.1016/j.oooo.2016.03.008; Preidl RH, Ebker T, Raithel M, Wehrhan F, Neukam FW, Stockmann P. Osteonecrosis of the jaw in a Crohn's disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report. BMC Gastroenterol. 2014 Jan;14:6. DOI:10.1186/1471-230X-14-6; Ramírez L, López-Pintor RM, Casañas E, Arriba Ld, Hernández G. New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws. Oral Health Prev Dent. 2015;13(5):385-93. DOI:10.3290/j.ohpd.a34055; Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. DOI:10.1016/j.joms.2014.04.031; Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May;5(2):119-33. DOI:10.1097/00054725-199905000-00008; Santos-Silva AR, Belizário Rosa GA, Castro Júnior Gd, Dias RB, Prado Ribeiro AC, Brandão TB. Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jun;115(6):e32-6. DOI:10.1016/j.oooo.2013.02.001; Sivolella S, Lumachi F, Stellini E, Favero L. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Res. 2013 May;33(5):1793-7.; Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014 Dec;12(12):1500-24. DOI:10.1016/j.ijsu.2014.07.014; Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 May;117(20):10970-5. DOI:10.1073/pnas.2005615117; http://dx.doi.org/10.3205/iprs000153; http://nbn-resolving.de/urn:nbn:de:0183-iprs0001537; http://www.egms.de/en/journals/iprs/2021-10/iprs000153.shtml

  11. 11
    Dissertation/ Thesis
  12. 12
    Conference
  13. 13
    Conference
  14. 14
    Academic Journal
  15. 15
    Academic Journal
  16. 16
  17. 17
    Academic Journal
  18. 18
    Academic Journal
  19. 19
    Conference
  20. 20